research use only
Cat.No.S4848
| Related Targets | Integrase Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease |
|---|---|
| Other Bacterial Inhibitors | Berberine BTZ043 Racemate Teicoplanin Pefloxacin Mesylate Ornidazole Proanthocyanidins Solithromycin Skatole Berberine Sulfate Furagin |
|
In vitro |
DMSO
: 100 mg/mL
(55.04 mM)
Water : 100 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 1816.69 | Formula | C88H100Cl2N10O28 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 171500-79-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | BI 397, MDL 63397 | Smiles | CNC1C(=O)NC2CC3=CC=C(OC4=C(OC5OC(C(O)C(O)C5NC(=O)CCCCCCCCC(C)C)C(O)=O)C6=CC(=C4)C(NC(=O)C(NC2=O)C7=CC(=CC(=C7Cl)O)OC8=CC=C1C=C8O)C(=O)NC9C(=O)NC(C(O)C%10=CC(=C(O6)C=C%10)Cl)C(=O)NC(C(=O)NCCCN(C)C)C%11 | ||
| In vitro |
Dalbavancin's mechanism of action involves the formation of a complex with the C-terminal d-alanyl-d-alanine of growing peptidoglycan chains, thereby inhibiting bacterial cell wall biosynthesis. In addition, this compound appears to have the unique ability to dimerise and anchor its lipophilic side chain in the bacterial membranes. It possesses more potent in vitro bactericidal activity than vancomycin or teicoplanin against many resistant Gram-positive organisms.
|
|---|---|
| In vivo |
Dalbavancin has a half-life of 170-210 h in human. It exhibits linear, dose-dependent pharmacokinetics in healthy adults, following the administration of single intravenous doses of this compound 140-1120 mg. Total protein binding of this chemical is concentration independent, reversible and estimated to be 93%. Animal studies regarding tissue distribution have demonstrated tissue concentrations reaching maximal levels within 24 h, with the highest concentrations in the liver and kidneys.
|
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05046860 | Recruiting | Osteoarticular Infection |
Centre Hospitalier Universitaire de Nice |
March 7 2022 | Not Applicable |
| NCT04959799 | Completed | Diabetes|Infection |
Aziende Chimiche Riunite Angelini Francesco S.p.A|Iqvia Pty Ltd |
January 2 2022 | -- |
| NCT04485676 | Completed | Skin Diseases Bacterial|Skin Diseases Infectious |
Angelini Farmacéutica|Effice Servicios Para la Investigacion S.L. |
July 15 2020 | -- |
| NCT06089044 | Completed | Prosthesis-related Infections |
Tourcoing Hospital |
January 1 2020 | -- |
| NCT03696901 | Terminated | Bacterial Infections |
Correvio International Sarl|AMS Advanced Medical Services GmbH|PrimeVigilance|Advanz Pharma |
November 21 2018 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.